RICE-ibrutinib in Relapsed DLBCL

STATUS

Recruiting
End date

Aug 21, 2023
participants needed

34
sponsor

Singapore General Hospital

Send

Updated on 27 January 2022

See if I qualify

lymphoma

gilbert's syndrome

glomerular filtration rate

anthracyclines

neutrophil count

b-cell lymphoma

anthracycline

ibrutinib

refractory diffuse large b-cell lymphoma

diffuse large b-cell lymphoma refractory

Summary

This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.

Description

All patients will receive R-ICE therapy for 2 cycles followed by PET-CT assessment (PET-2). Ibrutinib 560 mg will be added to the RICE regimen based on results of PET-2 as follows:

Patients in CR will continue with 2 more cycles of R-ICE and proceed onto ASCT. These patients will not receive ibrutinib.
In patients with stable disease or achieving a response that is less than CR, ibrutinib 560 mg will be added. The combination of ibrutinib-RICE will be given for 2 cycles and will be followed by PET-CT assessment (PET-4). Patients who achieve PR at this point will proceed onto ASCT.
Patients who have disease progression will be removed from the trial. Hematopoietic stem cell harvesting can be performed following count recovery at any cycle of R-ICE, but preferably cycle 2.

Transplant conditioning regimen will be with standard BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan).

Following ASCT, ibrutinib will be given as maintenance therapy for patients who did not achieve a CR at the time of PET-2 assessment. This will be continued for up to 1 year after ASCT.

Details

Condition	Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma Recurrent
Treatment	Ibrutinib-RICE
Clinical Study Identifier	NCT02955628
Sponsor	Singapore General Hospital
Last Modified on	27 January 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Histologically proven relapsed or refractory DLBCL (including transformed DLBCL)
	Patients who are eligible for autologous stem cell transplant as deemed by the Bone Marrow Transplant Team in the participating cites
	Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix A)
	Minimum life expectancy of 6 months
	Previously treated with anthracycline-based chemotherapy (unless contraindicated) with rituximab Written informed consent
	Must be at least 21 years old and able to sign informed consent form
	Adequate hematological function within 30 days prior to signing informed consent
	including
	Absolute neutrophil count (ANC) 1.0 x 109/L (1000/mm3) independent of growth factor support
	Platelets 100,000/mm3 or 50,000/mm3 if bone marrow involvement independent of transfusion support in either situation
	Hemoglobin 8 g/dL
	Biochemical values within the following limits
	Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 x upper limit of normal (ULN)
	Total bilirubin 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
	Serum creatinine 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault) 40 mL/min/1.73m2
	Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug
	Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study
	Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study
	Must be able to adhere to study visit schedules and other protocol requirements
	Male subject agrees to use an acceptable method for contraception for the duration of the study
Exclusion Criteria
	Concomitant use of any other investigational agent
	Contraindication to any drug contained in the regimen
	Myocardial infarction within 6 months prior to enrolment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant
	Clinically significant active infection
	Patients who are pregnant or breast-feeding
	Coexistent second malignancy or history of prior malignancy within previous 3 years (excluding non-melanoma skin tumors or in situ carcinoma of the cervix)
	Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures
	Major surgery within 4 weeks of randomization
	Known central nervous system lymphoma
	History of stroke or intracranial hemorrhage within 6 months prior to randomization
	Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)
	Requires treatment with strong CYP3A inhibitors
	Known inherited platelet function disorder
	Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
	Vaccinated with live, attenuated vaccines within 4 weeks of randomization
	Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics
	Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

lymphoma

gilbert's syndrome

glomerular filtration rate

refractory diffuse large b-cell lymphoma

diffuse large b-cell lymphoma refractory

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

RICE-ibrutinib in Relapsed DLBCL